Journal of Cardiovascular Magnetic Resonance | |
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone | |
Research | |
Ali Taher1  Elliott P Vichinsky2  John Wood3  Ellis Neufeld4  Alexis Thompson5  Eric A Macklin6  Blaine Moore7  Felicia Trachtenberg8  Hae-Young Kim8  Nancy Olivieri9  Patricia Evans1,10  John B Porter1,11  Patricia Giardina1,12  | |
[1] American University of Beirut, Beirut, Lebanon;Children’s Hospital & Research Center Oakland, Oakland, CA, USA;Children’s Hospital of Los Angeles, Los Angeles, USA;Children’s Hospital, Boston, MA, USA;Children’s Memorial Hospital, Chicago, IL, USA;Massachusetts General Hospital, Boston, MA, USA;National Heart, Lung and Blood Institute (NHLBI), Bethesda, MD, USA;New England Research Institutes, Watertown, MA, USA;Toronto General Hospital, University Health Network, Toronto, ON, Canada;University College London, London, UK;University College London, London, UK;Department of Haematology, University College London, UCL Cancer Institute, Paul O’Gorman Building, 72 Huntley Street, WC1E 6BT, London, UK;Weill Medical College of Cornell University, New York, NY, USA; | |
关键词: Thalassemia; Heart failure; Deferoxamine; Deferiprone; Combination; | |
DOI : 10.1186/1532-429X-15-38 | |
received in 2013-05-09, accepted in 2013-05-10, 发布年份 2013 | |
来源: Springer | |
【 摘 要 】
BackgroundEstablished heart failure in thalassaemia major has a poor prognosis and optimal management remains unclear.MethodsA 1 year prospective study comparing deferoxamine (DFO) monotherapy or when combined with deferiprone (DFP) for patients with left ventricular ejection fraction (LVEF) <56% was conducted by the Thalassemia Clinical Research Network (TCRN). All patients received DFO at 50–60 mg/kg 12–24 hr/day sc or iv 7 times weekly, combined with either DFP 75 at mg/kg/day (combination arm) or placebo (DFO monotherapy arm). The primary endpoint was the change in LVEF by CMR.ResultsImprovement in LVEF was significant in both study arms at 6 and 12 months (p = 0.04), normalizing ventricular function in 9/16 evaluable patients. With combination therapy, the LVEF increased from 49.9% to 55.2% (+5.3% p = 0.04; n = 10) at 6 months and to 58.3% at 12 months (+8.4% p = 0.04; n = 7). With DFO monotherapy, the LVEF increased from 52.8% to 55.7% (+2.9% p = 0.04; n = 6) at 6 months and to 56.9% at 12 months (+4.1% p = 0.04; n = 4). The LVEF trend did not reach statistical difference between study arms (p = 0.89). In 2 patients on DFO monotherapy during the study and in 1 patient on combined therapy during follow up, heart failure deteriorated fatally. The study was originally powered for 86 participants to determine a 5% difference in LVEF improvement between treatments. The study was prematurely terminated due to slow recruitment and with the achieved sample size of 20 patients there was 80% power to detect an 8.6% difference in EF, which was not demonstrated. Myocardial T2* improved in both arms (combination +1.9 ± 1.6 ms p = 0.04; and DFO monotherapy +1.9 ± 1.4 ms p = 0.04), but with no significant difference between treatments (p = 0.65). Liver iron (p = 0.03) and ferritin (p < 0.001) both decreased significantly in only the combination group.ConclusionsBoth treatments significantly improved LVEF and myocardial T2*. Although this is the largest and only randomized study in patients with LV decompensation, further prospective evaluation is needed to identify optimal chelation management in these high-risk patients.
【 授权许可】
CC BY
© Porter et al.; licensee BioMed Central Ltd. 2013
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311102065235ZK.pdf | 604KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]